- Home
- JLL vs ICLR Comparison
JLL vs ICLR Comparison
Compare JLL & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- ICLR
- Stock Information
- Founded
- JLL 1997
- ICLR 1990
- Country
- JLL United States
- ICLR Ireland
- Employees
- JLL N/A
- ICLR N/A
- Industry
- JLL Real Estate
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- JLL Finance
- ICLR Health Care
- Exchange
- JLL Nasdaq
- ICLR Nasdaq
- Market Cap
- JLL 14.1B
- ICLR 14.3B
- IPO Year
- JLL 1997
- ICLR 1998
- Fundamental
- Price
- JLL $289.84
- ICLR $160.59
- Analyst Decision
- JLL Buy
- ICLR Buy
- Analyst Count
- JLL 8
- ICLR 15
- Target Price
- JLL $338.29
- ICLR $211.36
- AVG Volume (30 Days)
- JLL 340.5K
- ICLR 967.3K
- Earning Date
- JLL 11-05-2025
- ICLR 10-22-2025
- Dividend Yield
- JLL N/A
- ICLR N/A
- EPS Growth
- JLL 31.91
- ICLR N/A
- EPS
- JLL 13.05
- ICLR 7.47
- Revenue
- JLL $25,317,800,000.00
- ICLR $8,102,602,000.00
- Revenue This Year
- JLL $12.21
- ICLR N/A
- Revenue Next Year
- JLL $8.43
- ICLR $0.89
- P/E Ratio
- JLL $22.07
- ICLR $21.90
- Revenue Growth
- JLL 12.51
- ICLR N/A
- 52 Week Low
- JLL $194.36
- ICLR $125.10
- 52 Week High
- JLL $322.37
- ICLR $231.89
- Technical
- Relative Strength Index (RSI)
- JLL 38.65
- ICLR 35.67
- Support Level
- JLL $274.71
- ICLR $159.19
- Resistance Level
- JLL $307.56
- ICLR $172.99
- Average True Range (ATR)
- JLL 8.40
- ICLR 8.46
- MACD
- JLL -2.28
- ICLR -2.70
- Stochastic Oscillator
- JLL 31.95
- ICLR 3.57
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.